Mantra Gold Coatings installs World's largest Gold-Plated Vimana Gopuram at Sri Lakshmi Narasimha Swamy Temple in Hyderabad

Handcrafted by Indian President Awardee artisan Ravindran Stapathi, hailing from the Vishwakarma community, who have been involved and engaged in the temple work for the past 15 generations and more, along with 105 plus direct artisans, helped craft and erect the World's largest Vimana Gopuram. Close to 70 kgs of gold was used along with 11000 kgs of copper, on a solid black granite carved Vimana Gopuram and total work duration, including the copper and gold plating of the Vimana Gopuram took close to 1000 days. 

The golden ornate monumental tower standing 55 feet in height, 66 kilograms in weight, spreading across 10,753 square feet, was unveiled by Telangana’s Chief Minister Shri A Revanth Reddy. This is considered to be Telangana's first gold plated Vimana Gopuram with 50 years warranty.

Mr Pankaj Bhandari, CEO of Mantra Gold Coatings said, “2025 is a significant year for Smart Creations, as it coincides with our celebration of 25 remarkable years of association with temples by consistently delivering Kalasams, Vimanas, Dwajasthambam , Golden chariots, Golden walls and Doors to 7800 temples, both in India and abroad, saving them gold worth Rs 4800 Crores. Today, we are greatly honoured that the Telangana Government, after a careful study of the Global Minamata convention on Mercury recommendations and Indian government’s related ban on the use of mercury in gold plating process, entrusted Smart Creations with the task of crafting Telangana’s first and World’s largest Golden Vimana Gopuram of Sri Lakshmi Narasimha Swamy Temple in Yadagirigutta.”

“This recognition is based on our track record of successfully executing gold plating projects using the modern Nano Tech Golden Deposition (NTGD) technology that adheres to eco-friendly practices by avoiding hazardous emissions like mercury oxide”, he added.

For more details, please visit: www.mantragoldcoatings.com.

About Eco- Friendly Nano Technology
The Vimana Gopuram is designed with Nano Tech Golden Deposition (NTGD) technology, the same as used in NASA / ISRO defense applications and equipment, including the Chandrayaan 1,2 & 3, India’s lander & rover mission to the moon. It minimizes the quantity of actual gold used in plating, which also increases the life and sheen of the gold plating. NTGD technology is used to gold plate temple domes, kalasams, gopuram & dhwajhasthambams in order to amplify the conductivity of these electromagnetic waves, making it superior. Smart Creations has done beautification work with Sashtra and traditional Designs- on Kalasam, Kodimaram , Doors, Chariots, Vahanam , Kavacham, Simhasam and much more in more than 59100 temples.

About Smart Creations
Smart creations have been associated with temples and kumbhabhishekams for more than 25 years and are a pioneer in gold plating for temples. Today with the traditional knowledge of special hand-chosen artisans combined with the latest technology, Smart creations are on a mission of upgrading temples to Golden temples. With a special R & D department, supported by a fully equipped factory, Smart creations have delivered Kalasams, Vimanams, Dhwajhasthambams, Golden chariots, Golden walls, Doors to 7800 temples in India and abroad. Special customization project management methodology is followed for each temple based on the gold plating requirement in terms of its size, the shine, the specific architecture of the temple, the geographical location of the temple in terms of whether it is near the sea, etc., including the temples uniqueness, their traditional rules, which are mandatory as per the specific temple and the time of delivery and execution. Till date, Smart Creations has helped 7800 temples save gold worth Rs 4800 Crores.

PM Shri Narendra Modi motivating Siddhartha Doshi on Nano fertilizer development
 

Beyond established fertilizer companies, pivotal contributors to India's ascendancy in this domain include innovative start-ups such as Ray Nano Science & Research Centre, focusing primarily on Nano technology-driven research. Actively engaged in developing avant-garde products leveraging nanotechnology for agricultural benefits, they have played a key role in shaping India's leadership.
 

With a commitment to innovation and technological progress, the organization has successfully introduced Nano Urea, utilizing its patented Green Technology, and initiated operations at its fully automated nano urea plant in Mogar, Gujarat, a mere five months after receiving Fertilizer Control Order permission.

Field efficacy studies have underscored the safety and positive impact of Ray Nano Science & Research Centre’s Nano Urea, positioning it as a non-toxic and environmentally friendly alternative. This product not only enhances crop productivity but also ensures the well-being of users and the surrounding environment.

Siddhartha Doshi, CEO of Ray Nano Science & Research Centre, stressed the significance of collaboration in the current era, asserting, "Instead of fostering competition, the emphasis now lies on collaborative efforts. As a research-centric company, Ray Nano Science is concentrating on fostering innovation and technological development." Doshi further highlighted the organization's strategic approach, intending to forge partnerships with fertilizer companies and Agri-Input giants, both within India and globally.

Looking forward, Ray Nano Science & Research Centre is poised to unveil a range of upcoming products, including Nano DAP and various other Nano fertilizers and nutrients. The organization's unwavering commitment to continuous innovation establishes it as a key player in shaping the future of Nano Agri Inputs on a global scale.

Nations worldwide are turning to India for expertise and collaborations in adopting Nano Agri Inputs to address their own agricultural challenges. The strides in nanotechnology-driven agricultural solutions align seamlessly with India's commitment to achieving the United Nations Sustainable Development Goals, particularly those related to zero hunger, clean water, and responsible consumption.

BML Munjal University (BMU), the Hero Group’s not-for-profit university, today announced a new B.Tech Program in Engineering Science for undergraduate students by the School of Engineering and Technology for 2020 - 24 batch. Given the exponential rate of technology the market demands agility, adaptability and interdisciplinary knowledge and skills from professionals. It has become increasingly important that students understand and apply concepts of engineering and science in a holistic manner to meet rapid advancements in technology and requirements of sustainable development. 

The new programme will focus on developing a rigor in the engineering science ‘fundamentals’ in the students. The students can pursue a specialization in a chosen interdisciplinary domain, such as Geospatial Science, Environmental Science, Materials Science, and Nano Science as per their interest, aptitude and readiness of the market for such new age courses. The applicants will have to fill in the online common application form available at www.bmu.edu.in/apply-page/, by March  26, 2020.

The primary highlights of the course would be that it would allow students to study subjects where sciences with engineering intersect. The new Engineering Science programme is also aimed to act as the foundation of future degree programmes themed towards “build your own degree”. These flexible and diverse “build your own degree” programmes are intended to allow freedom to prospective students in choosing structure and progress of their chosen degree programmes based on their interests, market demands, and rapidly changing educational environments. Globally, the engineering science programme is being offered by the University of Oxford and UC Berkley. In India, it is offered by IIT Hyderabad till date.

BMU has developed collaborations with a number of corporates, research organisations and international universities such as  Fraunhofer-Gesellschaft, Europe's largest applied research organisation, Warwick Manufacturing Group (WMG), University of Warwick, Purdue North West university, and four national R&D labs to ensure students are exposed to world class technology and can conduct research from the day they start the program. The university is also associated with Microsoft Intelligent Cloud Hub to further enrich the skills and expertise of the students in Artificial Intelligence, Data Science, Internet of Things and more.

The School of Engineering & Technology offers the following undergraduate programs:

• B.Tech in Computer Science & Engineering

• B.Tech in Electronics & Communication Engineering

• B.Tech in Mechanical Engineering

Students admitted in the above three programmes will have the option to choose any of the following specialisations,

• Data Science & Artificial Intelligence

• Cyber Security

• Internet Of Things

• Robotics & Automation

• Automobile Engineering

B.Tech in Engineering Science; Students can be admitted in of the following specialisations:

• Environmental Science

• Geospatial Science

• Materials Science

• Nano Science

Eligibility

BML Munjal University uses a holistic approach to evaluate students for each of its undergraduate programmes. For the B. Tech. programme, a student is evaluated basis the following:

• Class 10, Class 11 and Class 12 final examination scores as eligibility criteria

• If a student has taken the SAT or ACT exams, submitting those scores to BML Munjal University will enhance your chances of selection

• Performance in entrance/aptitude exams such as JEE, SAT etc. and Personal Interview

In addition, all applicants are required to submit the completed application form with all relevant enclosures including proof of payment. Short-listed candidates are called for a personal interview. The candidates are also screened for a case discussion/personal interview to determine final admissions.

Dr. Manoj K. Arora, Vice-Chancellor, BML Munjal University said, “World over people are gearing-up to invest in education and skill sets that is in sync with today’s demand for a better productive world. We have designed the new programme in “Engineering Science” that would combine sciences with engineering for the students to study the subjects where these fields intersect, thus, focus on developing a rigor in the engineering science ‘fundamentals’ in the students. The endeavour is to shape passionate, practical-oriented, industry-ready engineers who have the required skills to succeed as entrepreneurs or in industry. The students will be equipped with the expertise to create and manage enterprises that will thrive in the global economy. I am certain this would be well received both by the industry as well as the students.”

The students who have graduated from the B.Tech program have been placed with renowned corporations like Amazon, Dell, Hero, ITC Ltd, KPMG, Airtel, Indian Oil etc. across varied profiles with attractive packages. The students have sought industry internships across 150 plus companies in India.

The 50-acre, fully residential BML Munjal University campus is in Gurgaon, and attracts students from across India. The  University brings together outstanding academics, industry professionals, experienced researchers and the latest facilities to deliver a unique hands-on and multi-disciplinary learning experience. The university has a practical learning by doing model which aims at transforming students to become future leaders. The students also get to work on their personality, problem solving capabilities and multidimensional skill sets.

About BML Munjal University

BML Munjal University seeks to transform higher education in India by creating a world-class and innovative teaching, learning and research environment. Founded by the Hero Group in 2014 and mentored by Imperial College London, BMU is a not-for-profit initiative offering undergraduate and post-graduate courses. BMU’s aim is to nurture ethical leaders who are skilled, knowledgeable and have the life skills needed to lead organisations to success.

The various undergraduate and postgraduate programmes offered in the University are: B.Tech, BBA, B.A. (Hons) Economics, B. Com (Hons), B.A., LL.B. (Hons.), B.B.A., LL.B. (Hons.), MBA and Ph.D.

A product of 2mpower Health Management Services, GetActive tapp was launched after research by Mohammed Hussain Naseem and his team who cumulatively have more than 200 man years of experience in the segment. GetActive is the first bouquet of health products in India to be built ground up, with algorithms developed for Indian conditions.

GetActive tapp sports a sleek and trendy design which wirelessly syncs with your smartphone to deliver live fitness stats, which can be viewed on a personalised dashboard, downloadable both by iOS and Android phones. In addition, it allows you to accumulate currency for every step taken, which can be redeemed in GetActive’s partner ecosystem.

“Our goal is to create an ACTIVE India, where individuals walk towards their wellbeing. Today 10 million STEPS are clocked everyday on the GetActive platform. Our aim is to increase this count to a 100 billion STEPS every day in the next 30 months. This translates into 10 million ACTIVE Indians. We believe that when fitness is fun and non-regimental, it is more willingly accepted. Hence, our platform is designed towards high engagement through competition, challenge & rewards within the GetActive community”, said Mohammed Hussain Naseem, Founder & CEO of 2mpower Health Management Services (P) ltd. “Currently we have 15,000 users who have become our advocates. Our goal is to increase this number to 100,000 with the launch of tapp”, he added.

“It is our constant endeavour to help people "look good." Being fit and healthy is a step towards looking good. Sports and fitness being a large category with Myntra, is a clear indication of fitness conscious young India. Wearables are one such category which has been getting an extremely encouraging response from our customer segment. With GetActive tapp, we will introduce a whole new user experience to our consumers, that too exclusively. We look forward to a long term and mutually beneficial relationship”, added Ganesh Subramanian, Chief Operating Officer, Myntra.

As per a recent Accenture report, consumers in India were most interested in buying fitness monitors (80 percent), smart watches (76 percent) and Internet-enabled eyeglasses (74 percent). Industry observers believe that the wearables category is at a nascent stage in India, today. They estimate that the category is pegged at 50 Cr in 2014 and will reach a whopping 2500 Cr, by 2018. In the US, this industry will touch 50,000 Cr ($8.5B) during the same time.

Mohandas Pai, Chairman of Manipal Global Education and investor of an undisclosed amount in 2mpower Health Management Services, said "Wearable technology has shown good traction in US markets and it rates high in the mind of Indian consumers. I see immense opportunity in this sector. I believe GetActive is rightly poised to exploit this. The depth in the founding team, tremendous experience of working in large organizations, and passion to excel in their field of expertise will help GetActive to tap into this robust industry with its high-tech bouquets of products."

“The Quantified Self is a global movement since early 2011. It answers the most fundamental problem of self-insight through numbers. Analytics in healthcare is an emerging opportunity, and GetActive's big data can provide insights to improve quality of care as well as information on behavioural & data sciences”, said Prof Sadagopan, Director (President), IIIT Bangalore.

The GetActive platform on the web & mobile app is a powerful engagement tool and works with GetActive tapp, as well. It helps people build a community, who can compete, challenge and get rewarded for ACTIVE behaviour. Going forward the GetActive ecosystem will comprise of medical experts, nutritionist, health Insurance companies, hospitals & lifestyle companies.

GetActive product portfolio today consists of:

• GetActive tapp – Trendy band with choice of colors & automatic wireless sync

• GetActive Slim – an ultra slim clip-on with a sleep monitor

• GetActive eZ – Fitness for all, an easy to read large LCD display

GetActive aims at increasing and sustaining regular physical activity through quantification, gamification & social engagement. Over the last three years, GetActive has empowered more than fifteen thousand people towards a healthier and happier life across the country. It has also tied up with 28 corporates to improve the work productivity and efficiency of their employees.

About GetActive:

GetActive is an innovative technological initiative of 2mpower with an aim to make the exercise regimen a fun and involving experience. GetActive was born after three years of intensive research from people with a wealth of experience in wellness, disease management, information technology, motion sensor applications and behavior psychology. They believe in everything simple, scientific and fun.

Apart from retail consumers, GetActive partners with corporates, insurance companies, hospitals and fitness clubs. At the corporate level, it increases employee engagement through virtual walkathons, groupathons and other interesting challenges.

For media queries:

GetActive

Bijoe George

bijoe@2mpower.in

Six Degrees PR

Kripa Williams

kripaw@sixdegreespr.co.in

+91-9886486148

Venus Remedies Ltd, a global research-driven pharmaceutical company, has entered Singapore’s topical pain management market with a marketing authorisation and patent for its herbal nanotechnology-based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore.

Hailing the achievement, Venus Remedies Chairman and Managing Director Pawan Chaudhary said, “This is a great opportunity for us to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis.”

Chaudhary said the worldwide size of the topical pain management market is $4 billion, and, going by global projections, Trois has the potential of becoming a US $250-million product once launched internationally.

A product for topical use, Trois provides quick and lasting relief to patients suffering from rheumatic disorders, low back pain, osteoarthritis, rheumatoid arthritis, gout, knee pain, ankylosing spondylitis, fibromyalgia and pain originating from muscles and tendons. Currently, more than 1.5 billion people worldwide suffer from chronic pains of varying degree.

“Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30% more effective than conventional products, as proven by a series of toxicity and safety studies. It has 150% enhanced retention for longer effect, improved relief and better mobility,” said Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Remedies.

A pioneer in translational medicine, Venus has filed the product, process and use patent for Trois in 46 countries. While the company has already received patents from South Africa, New Zealand and now Singapore, it is on the verge of getting patent grants from the US, Canada and Europe.

Acknowledged as the Best Innovation for 2011 jointly by the Lockheed Martin Foundation, IC2 Texas, US, Indo-US Science and Technology Forum and the Department of Science and Technology, Government of India, Trois was launched in India last year. Having received a tremendous response from doctors and an encouraging feedback from patients in India, Trois is set to be a blockbuster product in the next few years.

The unique proposition of Trois is that it acts simultaneously on multiple inflammation-causing pathways to provide relief from pain and inflammation of multiple origins with very high efficacy as the particle size is less than the size of skin pores, thus making it easier to penetrate. Trois acts by selective cox-2 inhibition and inhibits transient receptor potential (TRP) activation and nociceptor stimulation (central and peripheral), thereby preventing cartilage degradation and bone erosion.

About Venus Remedies:

Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.

The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others.

Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report).

Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.

About Venus Medicine Research Centre:

The Venus Medicine Research Centre (VMRC) located at Baddi, Himachal Pradesh, is a fully equipped interdisciplinary drug discovery and development centre, duly approved by the Department of Scientific and Industrial Research (DSIR), Government of India.

The VMRC is committed to developing therapeutics to meet the challenges of antimicrobial resistance, targetted delivery of anticancer drugs and to provide solution to unmet medical needs in area of pain management. It has come up with many solutions for chronic diseases and has been awarded as the best innovator in hat trick by Indo US Science & Technology forum, Govt of India. It has achieved significant breakthrough in small molecule research for developing products helpful in combating antimicrobial resistance, utilising novel targets and adjuvants which synergise with other antibiotics and minimising potential for resistance for notable resistance barriers like ESBLs, “plasmid encoded carbapenem resistant metalo-beta-lactamases”, methicillin-resistant staphylococcus aureus (MRSA) and bacterial biofilms.

For further information, please contact:

Amardeep Singh Tiwana

Adfactors PR Pvt Ltd

Mobile: 9814046480

amardeep@adfactorspr.com

Under this licensing agreement, Cipla will be allowed to manufacture and market Sofosbuvir, Ledipasvir in 91 countries including its home markets India and South Africa under Cipla’s own brand names. It also covers countries like Egypt which has a high incidence of Hepatitis C. The countries within the agreement account for more than 100 million people living with hepatitis C globally representing 54% of the total global infected population. As per the agreement, Cipla has the option of receiving a technology transfer of the manufacturing process from Gilead.

Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said, “We want to ensure that all patients, particularly those in developing countries, get access to the most innovative, breakthrough medicines available. This partnership with Gilead emphasizes our ongoing commitment to provide access to medicines for patients when they need it. The prevalence of Hepatitis C is widely spread across the world and there is a need for Cipla to step in and provide broader access to medicines like Sofosbuvir, Ledipasvir. We look forward to manufacturing the drug in India and offer the drug to patients at a competitive price.”

According to World Health Organization (WHO), 130-150 million people globally have Hepatitis C infection. In India alone, it is estimated that 10-20 million patients are infected with Hepatitis C which is several fold greater than those with HIV/AIDS. A significant proportion of the patients who are chronically infected develop liver cirrhosis and liver cancer. Sofosbuvir is a new antiviral drug which in combination therapy has shown to have higher cure rates. It represents a breakthrough in the treatment of hepatitis C.

Sofosbuvir was approved by the U.S. Food and Drug Administration (FDA) in December 2013 and by the European Commission in January 2014. Sofosbuvir, in combination with other agents, offers a cure with a short-term course of treatment with few side effects and without the need for injections.

Earlier this year, Cipla licensed Raltegravir from MSD and there are already several patients on treatment who earlier would not have had access to third line therapy for HIV/AIDS. Cipla will continue to ensure access to medicines for patients suffering from infectious diseases across the

world.

About Cipla Limited:

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 70 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla’s turnover in 2013-14 was 1.7 billion USD.

Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination antiretroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.

Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UK MHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.

Disclaimer:

Except for the historical information contained herein, statements in this release and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and

uncertainties include, but are not limited to our ability to successfully implement our strategy, our

growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Cipla Limited does not

undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Media Contact:

Charlotte Chunawala

Corporate Communications

Mobile: +91 7506257377

E Mail id: charlotte.chunawala@cipla.com

Jaisingh Balakrishnan

Corporate Communications

Mobile: +91 9833836185

E Mail id: jaisingh.krishnan@cipla.com

The Jasubhai Group is known for its strong domain knowledge across sectors as diverse as Chemicals & Processing, Oil & Gas, Refining, Engineering Procurement & Construction, Automation & Process Control, Pharma & Biotechnology, Water, Shipping & Maritime, Power and Infrastructure & Design.

Mr. Maulik Jasubhai during his tenure at the Jasubhai Group also founded & published the Jasubhai Digital Media, a pioneer in IT Media & Online Media with preeminent brands like Chip, Digit, ZDNet India, CTO Forum and CRN. Prior to his position at the Jasubhai Group, Mr. Maulik Jasubhai worked with Fisher Rosemount, a Process Automation Division of Emerson Electric--a US-based Fortune 500 company. Under his aegis, the Jasubhai Group has entered the fast-growing Middle East market and has already set up manufacturing operations in other international markets to serve the growing engineering demands. Mr. Maulik Jasubhai is also the Hon. Vice Consul of Austria in Mumbai, since the year 2000. Mr. Maulik Jasubhai holds a degree in Industrial Management from Carnegie Mellon University and an MBA from the prestigious Wharton Business School. 

Jasubhai Group: Established in 1966 and headquartered in Mumbai, the Jasubhai Group is focused on two core business areas: Engineering & Manufacturing, Business & Technology Media. The Group comprises of Jasubhai Engineering Private Ltd (JEPL), CHEMTECH Foundation, Jasubhai Media and the Jasubhai Foundation. The Group has a pan-India presence across major cities, as well as overseas in Dubai, Oman and Qatar. www.jasubhai.com

Jasubhai Engineering Pvt. Ltd (JEPL): The engineering arm of the Jasubhai Group is one of India’s leading engineering solutions provider in the field of instrumentation, process automation, contract manufacturing & water technology, for the entire Process Industries. JEPL was the majority JV partner of the Emerson Process Management India (Division of Emerson, a US$25bn Fortune 500 company) from 1981 to 2012. JEPL has an expanding presence across 10 locations in India and overseas, with over 300 employees and 2 manufacturing facilities and Engineering Center, in India and in Dubai. Since its conception in 1967, JEPL has established multiple divisions that include Combustion Engineering, Contract Manufacturing, Material Handling, Process Equipment, Process Automation, Oil & Gas Services and Water Technology. It also manufactures a wide range of products such as industrial oil and gas-fired burners; automatic weighing, bagging, conveying and other material handling systems; valves and valve automation systems, high pressure process equipment & oil and gas anti-corrosion services. JEPL also has an ABM division that specializes in offering precision component manufacturing services for Process and Aerospace Industries. For more information, please visit www.jasubhaiengineering.com

CHEMTECH Foundation: Promoted by the Founder and Chairman, Mr. Jasu Shah; CHEMTECH is India's largest non-profit industry association since 1975, known for its unique platform for business interactions & strategic alliances. The internationally acclaimed ‘CHEMTECH World Expo’ series of international exhibitions, conferences & trade fairs have grown to become the 2nd largest global event (after Achema in Germany) for the chemicals processing industry. CHEMTECH World Expo focuses on exchange of information and innovative ideas pertinent to sectors such as Chemicals & Processing, Pharma & Biotech, Oil & Gas, Refining & Petrochemicals, Power, Water, Shipping, Infrastructure & Design, Engineering Procurement & Construction (EPC) and Industry Automation Control.  At this landmark event, the robust exchange of insights and technological innovations that take place between the Indian industry and partner countries plays a vital role in shaping the future of those industries. www.chemtech-online.com

Jasubhai Media:  The media arm of the Jasubhai Group is one of India's leading publishers of Business-to-Business and Special Interest and Technical Journals. The Jasubhai Group has been publishing niche magazines in all major industrial segments, including prestigious and outstanding titles like Chemical Engineering World, Chemical Products Finder, Offshore World, Pharma Bio World, Who's Who, Indian Architect & Builder and 3610 Design Conferences.

Jasubhai Foundation: Established in 1984, the Jasubhai Foundation is a registered Charitable Trust funded by the Jasubhai Group of Companies and its Founder, Mr. Jasu Shah. Its core areas include Education, Medicine, Arts & Culture, Indian Heritage and Rural Development. The Foundation supports activities from primary to advanced professional education. In the field of healthcare, the Foundation promotes medical assistance for people in need, financially supports the Eye Hospital in Kalol, North Gujarat, and is the Founding Patron of the Sri Shanmukhananda Sabha’s Medical Center in Matunga, Mumbai. Jasubhai Foundation is also a major supporter and Patron of the NCPA and the Sri Shanmukhananda Sabha in Mumbai.

Media Contact:

Anand K. Lalwani

REPUTE

Public Affairs & CSR Solutions

T: +91 22 2605 9019 | M: +91 8108345508

E: anand.lalwani@reputesolutions.com

Venus Pharma GmbH, Germany, a wholly owned subsidiary of Venus Remedies Limited, a research-driven global pharmaceutical company based in Panchkula, has entered into a distribution-cum-outlicensing agreement with Mylan for marketing its generic broad-spectrum antibiotic, meropenem, in three European countries. This deal with Mylan, the world’s third largest generic drug manufacturer, will enable Venus Remedies to market meropenem in Denmark, Sweden and Finland for a period of five years.

“Under this non-exclusive marketing agreement, we will manufacture the drug at our Baddi facility, which recently got a renewed European Union Good Manufacturing Practices (GMP) certification, while the batch release and logistics will be handled by our Germany facility Venus Pharma GmbH. The addition of territories on the basis of strategic tie-ups with our existing partners has re-established the faith of our customers in our quality standards and timely deliveries. This joint venture will further help Venus Pharma GmbH and its collaborators in maintaining their market position to figure among the top five players with around 30% share in meropenem markets in countries like Germany, France and UK,” said Ashutosh Jain, Executive Director-cum-Chief Operating Officer (COO), Venus Pharma GmbH, Werne, Germany.

Venus already has a non-exclusive marketing tie-up with Mylan for the same product in France, where the drug has been successfully launched and is contributing to the company’s top and bottom lines.

Meropenem, the global annual generic sales of which stood at USD 1,879 million in 2012 and are estimated to grow at a compounded annual growth rate of 7.5% to reach around USD 2,100 million in 2014-15, is a broad-spectrum antibiotic used in ICU infections as a last resort for the treatment of life-threatening infections. As per IMS Health, the market size for this product in Denmark, Sweden and Finland is approximately Euro 12.54 million.

Meropenem belongs to the carbapenem class of antibiotics and can be used effectively in both children and adults. Venus has successfully launched this drug in major European markets under its own brand name and through strategic alliance partners by way of tie-ups.

Venus Remedies has secured more than 60 marketing authorisations for meropenem throughout the world from countries like the UK, France, Austria, Italy, Denmark, Finland, Ireland, Germany, Netherlands, Poland, Slovenia, Slovakia, Sweden, Portugal, Czech Republic, Cyprus, New Zealand and Mexico, among others. The company recently got its first Australian marketing authorisation for this product in tie-up with Lupin. Venus is now all set to receive marketing approvals for meropenem from Switzerland and South Africa.

“The top line of Venus Pharma GmbH, Germany has generated USD 15.6 million in the last one year, thereby becoming a profit-making unit of Venus Remedies. We are pleased to join hands with Mylan and expect Venus Pharma GmbH to achieve a significant increase in turnover in the coming quarters,” said Pawan Chaudhary, Chairman and Managing Director (CMD), Venus Remedies Limited.

The company is holding talks for more strategic tie-ups in regulated markets with multinational companies that are already operating in these territories. The facilities of Venus in India have a capacity of manufacturing 16 million units of meropenem per annum on single-shift basis. The company is currently utilising 50% of its capacity. Thus, it has sufficient excess capacity to meet the growing market needs as it prepares for more marketing authorisations and widespread expansion of its marketing network across the globe.

About Venus Remedies:

Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.

The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others.

Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report).

Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.

About Venus Medicine Research Centre:

The Venus Medicine Research Centre (VMRC) located at Baddi, Himachal Pradesh, is a fully equipped interdisciplinary drug discovery and development centre, duly approved by the Department of Scientific and Industrial Research (DSIR), Government of India.

The VMRC is committed to developing therapeutics to meet the challenges of antimicrobial resistance, and has come up with many solutions. It has achieved significant breakthrough in small molecule research for developing products helpful in combating antimicrobial resistance, utilising novel targets and adjuvants which synergise with other antibiotics and minimising potential for resistance. Significant breakthroughs have been achieved by the VMRC in antibiotic adjuvant entities for notable resistance barriers like ESBLs, “plasmid encoded carbapenem resistant metalo-beta-lactamases”, methicillin-resistant staphylococcus aureus (MRSA), bacterial biofilms and C. difficile infection.

For further information, please contact:

Amardeep Singh Tiwana

Adfactors PR Pvt Ltd

9814046480

amardeep@adfactorspr.com

An offshore contract valued at Rs. 1,340 crore from the Oil & Natural Gas Corporation (ONGC), won against international competitive bidding, includes engineering, procurement, construction and installation of five wellhead platforms at the Mumbai High North field of ONGC. The project, part of ONGC’s strategy to re-develop Phase-III of Mumbai High North field to enhance production from existing reservoirs, is scheduled to be completed by March, 2016.

In the onshore segment LTHE has secured a contract valued at approximately Rs. 580 crore from a leading company engaged in hydrocarbon downstream processing. LTHE will carry out engineering, procurement and construction of a dual service cryogenic storage tank facility, suitable for liquid ethane and liquefied natural gas and engineering work for the balance of the facilities to be installed at the client’s manufacturing complex.

Background:

Larsen & Toubro is a major Indian multinational in technology, engineering, construction, manufacturing and financial services, with global operations. Its products and systems are marketed in over 30 countries worldwide. A strong, customer–focused approach and the constant quest for top-class quality have enabled L&T to attain and sustain leadership in its major lines of business over seven decades.

• Fujitsu outlines strategy to lead India’s High-Performance Computing (HPC) market.

• Company targets 100 percent growth in HPC market segment in India.

• Announces setting up a new Fujitsu HPC Competency Center in India for High-Performance Computing solutions, the first such center in India by a technology vendor.

• Appoints Fujitsu’s Select Experts, highest tier of Fujitsu Partner program for greater HPC market outreach and fulfilment.

Fujitsu, the leading Japanese information and communication technology (ICT) company, today announced that it is charting an aggressive strategy to build its share in the High Performance Computing (HPC) market segment in India, buoyed by the traction it has gained in the market. The company has planned investments across customer services and engagement, partnerships and training, with an aim to double its revenues in the HPC segment. As part of this strategy, Fujitsu will open the Fujitsu HPC Competency Center in Bangalore – the first such by a technology vendor in India, and Fujitsu’s fifth such center globally. It also announced strengthening exclusive partnerships with select partners in India. These announcements were made today at the Fujitsu World Tour 2014 event in Delhi.

Fujitsu envisages that demand for HPC in India will stem from application areas such as – advanced drug discovery, seismic engineering for oil exploration, automotive design, industrial manufacturing, aeronautical and defence research and design, mathematical modeling from scientists working on advanced theories, chemical and physical engineering formulation, advanced weather forecasting, and government-specific demand areas.

Fujitsu’s new HPC Competency Center in Bangalore is part of the company’s vision to expand the possibilities of HPC in potential global markets, and in line with its aim to grow in the Indian market. The Fujitsu HPC Competency Center will allow scientists, analysts and engineers in India to leverage the power of HPC to solve complex science, engineering, and business problems using applications that require high bandwidth, low latency networking, and very high compute capabilities. By doing so, Fujitsu is enabling access to HPC infrastructure for the scientific and technical community, private and public organisations in India, who otherwise do not have the resources to build their own HPC infrastructure, or have the in-depth technical expertise to execute HPC models.

The investment made by Fujitsu in the new Fujitsu HPC Competency Center includes establishing a high-tech cluster consisting more than 750 cores of processing, along with storage and InfiniBand networks, and highly skilled technical talent in the area of HPC. The high-tech cluster is powered by the extreme reliability of proven Fujitsu PRIMERGY servers.

As part of its go-to-market strategy for HPC in India, Fujitsu has set clarity among its partners as part of its SELECT Partner Program. It has appointed ‘SELECT Expert’ partners for HPC Solutions in India, which is the highest level of the Fujitsu SELECT Partner program.

Naoya Tamura, General Manager, Global HPC, Fujitsu Technology Solutions GmbH, said, “The use of HPC in an organisation or in a country is a strong indicator of the scientific and technical prowess and ambition, and enterprises in the private and public sectors in India are showing very strong inclinations to adopt HPC. We are keen to power them with the huge and efficient computing ability and technical knowledge to tackle problems of high scientific and business value.”

Andy Stevenson, Territory Leader – Middle East and India, Managing Director for Fujitsu, India, said, “Fujitsu is the most experienced and largest provider of HPC solutions in Asia, a leading HPC vendor in Europe, and it is natural for us to invest in markets which show promise. The Indian market for HPC solutions is vibrant, owing to an increasing focus from the Government to become scientifically advanced and prepared, and sectors such as manufacturing and design, pharma and telecom which value the importance of advancements, new discoveries and time-to-market. We already have a strong presence in HPC Solutions in India, and look to grow that significantly.”

This announcement follows the introduction of the Fujitsu HPC Simplicity concept in India in 2013, which combines the Fujitsu Software HPC Cluster Suite (HCS), an immediately optimized x86 HPC cluster solution based on Fujitsu PRIMERGY servers, with a new graphical user interface-based front end.

The new Fujitsu HPC Competency Center in Bangalore will be open to customers and partners from November, 2014.

Online resources

• Read the Fujitsu blog: http://blog.ts.fujitsu.com

• Follow Fujitsu on Twitter: http://www.twitter.com/Fujitsu_Global

• Follow us on LinkedIn: http://www.linkedin.com/company/fujitsu

• Find Fujitsu on Facebook: http://www.facebook.com/FujitsuICT

• Fujitsu pictures and media server: http://mediaportal.ts.fujitsu.com/pages/portal.php

• For regular news updates, bookmark the Fujitsu newsroom: http://ts.fujitsu.com/ps2/nr/index.aspx

About Fujitsu:

Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 162,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.8 trillion yen (US$46 billion) for the fiscal year ended March 31, 2014. For more information, please see http://www.fujitsu.com. 

About Fujitsu CEMEA&I:

In Continental Europe, the Middle East, Africa and India, Fujitsu is the leading IT infrastructure provider with a presence in all key markets serving large, medium-sized and small businesses. The company offers a full portfolio of IT products, business solutions and services, ranging from workplace systems to datacenter solutions, managed services, and cloud-based software and solutions. In CEMEA&I Fujitsu employs approximately 13,000 people and is part of the global Fujitsu Group. For more information, please see:ts.fujitsu.com/aboutus.

All other company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.

Media contacts:

Santhosh NS

Fujitsu India Pvt. Ltd.

Tel: +91 9845186208

E: santhosh.ns@ts.fujitsu.com

Shatarupa Maitra

Six Degrees PR

Tel: +91.8095603506

E: shatarupam@sixdegreespr.co.in

Kiran Balasubramanian

Six Degrees PR

Tel: +91.9886771250

E: kiranb@sixdegreespr.co.in